Drug
LEO 29102
LEO 29102 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
LEO 29102 Cream in the Treatment of Atopic Dermatitis
NCT01037881
terminatedphase_1
Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.
NCT01447758
completedphase_1
LEO 29102 Single and Multiple Dose Study by Dermal Application
NCT00891709
completedphase_1
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102
NCT01423656
Clinical Trials (4)
Showing 4 of 4 trials
NCT01037881Phase 2
LEO 29102 Cream in the Treatment of Atopic Dermatitis
NCT01447758Phase 1
Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.
NCT00891709Phase 1
LEO 29102 Single and Multiple Dose Study by Dermal Application
NCT01423656Phase 1
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4